184 related articles for article (PubMed ID: 16207994)
1. Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia.
McDermott JL; Martini I; Ferrari D; Bertolotti F; Giacomazzi C; Murdaca G; Puppo F; Indiveri F; Varnier OE
J Clin Microbiol; 2005 Oct; 43(10):5272-4. PubMed ID: 16207994
[TBL] [Abstract][Full Text] [Related]
2. Absence of genetic diversity reduction in the HIV-1 integrated proviral LTR sequence population during successful combination therapy.
Ibáñez A; Clotet B; Martínez MA
Virology; 2001 Mar; 282(1):1-5. PubMed ID: 11259184
[TBL] [Abstract][Full Text] [Related]
3. 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo.
Pauza CD; Trivedi P; McKechnie TS; Richman DD; Graziano FM
Virology; 1994 Dec; 205(2):470-8. PubMed ID: 7975248
[TBL] [Abstract][Full Text] [Related]
4. Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.
Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Palmisano L; Andreotti M; Andreoni C; Giuliano M; Gatti F; Boldrin C; Palù G; Vullo V; Vella S; Andreoni M
J Clin Microbiol; 2005 Dec; 43(12):6183-5. PubMed ID: 16333125
[TBL] [Abstract][Full Text] [Related]
5. Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker.
Bushman F
AIDS; 2003 Mar; 17(5):749-50. PubMed ID: 12646799
[No Abstract] [Full Text] [Related]
6. Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA.
Cara A; Vargas J; Keller M; Jones S; Mosoian A; Gurtman A; Cohen A; Parkas V; Wallach F; Chusid E; Gelman IH; Klotman ME
Virology; 2002 Jan; 292(1):1-5. PubMed ID: 11878902
[TBL] [Abstract][Full Text] [Related]
7. Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA.
Cara A; Maggiorella MT; Bona R; Sernicola L; Baroncelli S; Negri DR; Leone P; Fagrouch Z; Heeney J; Titti F; Cafaro A; Ensoli B
Virology; 2004 Jul; 324(2):531-9. PubMed ID: 15207638
[TBL] [Abstract][Full Text] [Related]
8. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.
Delaugerre C; Charreau I; Braun J; Néré ML; de Castro N; Yeni P; Ghosn J; Aboulker JP; Molina JM; Simon F;
AIDS; 2010 Sep; 24(15):2391-5. PubMed ID: 20683319
[TBL] [Abstract][Full Text] [Related]
9. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.
Carr JM; Cheney KM; Coolen C; Davis A; Shaw D; Ferguson W; Chang G; Higgins G; Burrell C; Li P
J Clin Microbiol; 2007 Apr; 45(4):1288-97. PubMed ID: 17314225
[TBL] [Abstract][Full Text] [Related]
10. Evidence for gene expression by unintegrated human immunodeficiency virus type 1 DNA species.
Brussel A; Sonigo P
J Virol; 2004 Oct; 78(20):11263-71. PubMed ID: 15452245
[TBL] [Abstract][Full Text] [Related]
11. Unintegrated viral DNA as a marker for human immunodeficiency virus 1 infection in vivo and in vitro.
Nandi JS
Acta Virol; 1999 Dec; 43(6):367-72. PubMed ID: 10825926
[TBL] [Abstract][Full Text] [Related]
12. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
[TBL] [Abstract][Full Text] [Related]
13. Failure to eradicate HIV despite fully successful HAART initiated in the first days of life.
Viganò A; Trabattoni D; Schneider L; Ottaviani F; Aliffi A; Longhi E; Rusconi S; Clerici M
J Pediatr; 2006 Mar; 148(3):389-91. PubMed ID: 16615974
[TBL] [Abstract][Full Text] [Related]
14. Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo.
Fischer M; Trkola A; Joos B; Hafner R; Joller H; Muesing MA; Kaufman DR; Berli E; Hirschel B; Weber R; Günthard HF;
Antivir Ther; 2003 Apr; 8(2):97-104. PubMed ID: 12741621
[TBL] [Abstract][Full Text] [Related]
15. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
[TBL] [Abstract][Full Text] [Related]
16. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.
Reigadas S; Andréola ML; Wittkop L; Cosnefroy O; Anies G; Recordon-Pinson P; Thiébaut R; Masquelier B; Fleury H
J Antimicrob Chemother; 2010 Mar; 65(3):434-7. PubMed ID: 20051476
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection.
Brussel A; Mathez D; Broche-Pierre S; Lancar R; Calvez T; Sonigo P; Leibowitch J
AIDS; 2003 Mar; 17(5):645-52. PubMed ID: 12646786
[TBL] [Abstract][Full Text] [Related]
18. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
[TBL] [Abstract][Full Text] [Related]
19. Increased number of single-LTR HIV-1 DNA junctions correlates with HIV-1 antigen expression and CD4+ cell decline in vivo.
Jurriaans S; de Ronde A; Dekker J; Cornelissen M; Goudsmit J
J Med Virol; 1995 Jan; 45(1):91-8. PubMed ID: 7714497
[TBL] [Abstract][Full Text] [Related]
20. Sustained viremia during highly active antiretroviral therapy with accelerated proviral DNA decay in the setting of infection with syphilis.
Padte N; Rowe L; Hurley A; Simon V; Markowitz M
AIDS; 2003 Sep; 17(14):2143-5. PubMed ID: 14502027
[No Abstract] [Full Text] [Related]
[Next] [New Search]
